Crizotinib Efficacy After Progression With Entrectinib in ROS1-Positive Lung Cancer: A Case Report

Crizotinib and entrectinib are approved tyrosine kinase inhibitors by the FDA to treat advanced-stage ROS1-positive non-small cell lung cancer (NSCLC). Although, entrectinib could be used after crizotinib, it is unknown whether crizotinib is effective after entrectinib. We report a case of NSCLC wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Taban, Hakan, Guven, Deniz Can, Kılıçkap, Saadettin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9452052/
https://www.ncbi.nlm.nih.gov/pubmed/36106272
http://dx.doi.org/10.7759/cureus.27828

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9452052/
https://www.ncbi.nlm.nih.gov/pubmed/36106272
http://dx.doi.org/10.7759/cureus.27828

Ejemplares similares